Global Markets Latest Research Reports: Drugs For Hormonal Replacement Therapy Market Report

Showing posts with label Drugs For Hormonal Replacement Therapy Market Report. Show all posts

Sep 27, 2018

Growth Rate Expected To Increase For The Genito-urinary Drugs Market By 2021 As Per TBRC’s Latest Report (Companies Included: Daiichi Sankyo Company, Limited, Pfizer Inc, Bayer AG, Astellas Pharma Inc.)

The genitourinary drugs market covers drugs that are used in the treatment of diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, Reno vascular diseases, benign prostate diseases, and other related diseases.

The global genitourinary drugs market has shown moderate growth in the past years with a CAGR of over 4%. The year 2017 recorded highest ever market value in this industry as per TBRC’s inhouse consultants.

TBRC’s latest report show the historic and future trends in the market for each year with sourced reasons to support the growth claims.

The report also shows the genitourinary drugs market to grow at a higher CAGR by 2021 as compared to 2017, along with geographies best suited for investments with highest return rate.

Sample report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=274&type=smp

The global genito-urinary drugs market is expected to grow at a compound annual growth rate (CAGR) of around 6%. This growth is mainly due to growing genitourinary disorders like chronic kidney disease (CKD). Going forward, the number of pipeline drugs (ABT-614, Abbott Laboratories and EOS789, Chugai Pharmaceutical) are expected to increase with constant improvements in healthcare infrastructure. Novel drugs such as Cialis which are considerably more effective than the drugs used in multiple-drug therapies, and are affordable in cost are expected to fuel the growth of this market.

Request for discount: https://www.thebusinessresearchcompany.com/sample.aspx?id=274&type=discount

TBRC’s latest report will cover in depth understanding and calculated impacts of each market factor on a global as well as regional level, to analyze the best investment strategy for this market.

Companies included in the report are Daiichi Sankyo Company, Limited, Pfizer Inc, Bayer AG and Astellas Pharma Inc.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Jul 3, 2018

Genitourinary Drugs Global Market Is Expected To Grow Close To $82 Billion By 2021 According To TBRC’s Latest Report

The genitourinary drugs market covers drugs that are used in the treatment of diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, renovascular diseases, benign prostate diseases, and other related diseases.

Read the report at

https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report-2018

The major reason why the global genitourinary drugs market will increase from $63 billion in 2017 to close to $82 billion by 2021 is growth of genitourinary disorders like chronic kidney disease CKD and the number of pipeline drugs.

In the report, the global genitourinary drugs market is divided into eight segments namely, hormonal contraceptives, drugs for hormonal replacement therapy, drugs for infections and others, drugs for benign prostatic hypertrophy, drugs for erectile dysfunction, drugs for urinary incontinence and overactive bladder, drugs for infertility, and diuretics. While the first and the second segments account for nearly three-fifth of the market share, the remaining share is attributed to the other six segments.

Download a sample of the report at

https://www.thebusinessresearchcompany.com/sample.aspx?id=253&type=smp

The USA was the largest country in the genitourinary drugs market in 2017, accounting for around 30% of the market share. This can be attributed to the high prevalence of urinary diseases like chronic kidney diseases, erectile dysfunction and infertility in the country. Moreover, public awareness and expenditure on health care is high in the USA. China and Italy followed the USA as the next largest countries in the market.

The genitourinary drugs market is fragmented with a number of large and small drugs organizations. The top five competitors in the market made up 14% of the total market in 2017. Daiichi Sankyo Company, Limited was the largest competitor of the market, followed by Pfizer Inc. and Bayer AG. Daiichi Sankyo Company is involved in the research, development and marketing of pharmaceutical products for osteoporosis, ulcer treatment, alzheimer’s disease, anti-influenza treatment, hypertension and diabetes. The company is headquartered in Tokyo, Japan and employs 14,670 people.